Paid Clinical Trials for Blood Disorders, Myelodysplastic Syndromes

Paid Clinical Trials and Focus Groups by Category

Find Paid Clinical Trials

Find Paid Clinical Trials All Categories ... Medical Conditions » ... Blood Disorders » ... Myelodysplastic Syndromes


  • Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)

    Condition:   Leukemia
    Intervention:   Drug: Alemtuzumab
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified August 2010
  • Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   De Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes
    Interventions:   Procedure: umbilical cord blood transplantation;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Procedure: ex vivo-expanded cord blood progenitor cell infusion;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
    Sponsor:   Fred Hutchinson Cancer Research Center
    Recruiting - verified August 2010
  • Short-Term Fasting Before Chemotherapy in Treating Patients With Cancer

    Condition:   Lymphoma
    Interventions:   Other: enzyme-linked immunosorbent assay;   Genetic: microarray analysis;   Other: questionnaire administration;   Other: preventative dietary intervention
    Sponsor:   Mayo Clinic
    Recruiting - verified August 2010
  • Reduced-intensity, Partially Mismatched, BMT With Flu-bu and Post Hi-Cy

    Conditions:   Lymphoma;   Leukemia;   Myelodysplastic Syndrome
    Intervention:   Drug: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus,
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified September 2010
  • Clofarabine, Cytarabine, and G-CSF in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

    Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   De Novo Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Biological: filgrastim;   Drug: clofarabine;   Drug: cytarabine
    Sponsor:   Fred Hutchinson Cancer Research Center
    Recruiting - verified August 2010
  • Does Maitake Mushroom Extract Enhance Hematopoiesis in Low-Risk, Untreated Myelodysplastic Patients?

    Condition:   Myelodysplastic Syndrome
    Intervention:   Other: Maitake
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   YUKIGUNI COMPANY;   Weill Medical College of Cornell University
    Recruiting - verified September 2010
  • Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   Atypical Chronic Myeloid Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   De Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Myelodysplastic/Myeloproliferative Disease, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma
    Interventions:   Drug: plerixafor;   Biological: filgrastim;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsor:   Fred Hutchinson Cancer Research Center
    Recruiting - verified August 2010
  • Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

    Condition:   Myelodysplastic Syndrome
    Interventions:   Drug: Ezatiostat Hydrochloride;   Drug: Lenalidomide (Revlimid®)
    Sponsor:   Telik
    Recruiting - verified February 2010
  • A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q

    Condition:   Anemia
    Interventions:   Drug: Lenalidomide;   Other: Placebo
    Sponsor:   Celgene Corporation
    Recruiting - verified September 2010
  • Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
    Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
    Recruiting - verified September 2010
  • Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer

    Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: Total body irradiation;   Biological: Umbilical cord blood unit with C3a fragment;   Biological: Unmanipulated UCB Unit
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified August 2010
  • A Study Of PF-04449913 In Select Hematologic Malignancies Or With Dasatinib In Chronic Myeloid Leukemia (CML)

    Condition:   Hematologic Malignancies
    Interventions:   Drug: PF-04449913;   Drug: dasatinib
    Sponsor:   Pfizer
    Recruiting - verified August 2010
  • Combined Haploidentical-Cord Blood Transplantation for Adults and Children

    Conditions:   Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma;   Lymphoma
    Interventions:   Drug: Fludarabine-Melphalan & Rabbit antithymocyte globulin;   Procedure: Stem Cell Transplant;   Procedure: Stem Cells Collections
    Sponsor:   University of Chicago
    Recruiting - verified August 2010
  • Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

    Conditions:   Preleukemia;   Myeloproliferative Disorders;   Lymphoma;   Myeloma;   Graft Versus Host Disease
    Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Drug: Campath
    Sponsor:   University of Chicago
    Recruiting - verified August 2010
  • Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

    Conditions:   Advanced Hematologic Malignancies;   Leukemia;   Preleukemia
    Interventions:   Drug: Clofarabine;   Drug: Melphalan;   Drug: Campath;   Procedure: Stem Cell Transplant
    Sponsor:   University of Chicago
    Recruiting - verified August 2010
  • Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2010
  • Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

    Conditions:   Graft Versus Host Disease;   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Fludarabine Phosphate;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation (TBI);   Other: Magnetic Affinity Cell Sorting;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation
    Sponsors:   Yale University;   National Cancer Institute (NCI);   Fred Hutchinson Cancer Research Center
    Recruiting - verified August 2010
  • Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies

    Conditions:   Acute Myeloid Leukemia;   Infantile Leukemia (Both AML and ALL);   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasms;   Chronic Myeloid Leukemia, in Blastic Crisis;   Biphenotypic Leukemia
    Interventions:   Drug: Sorafenib;   Drug: Cytarabine;   Drug: Clofarabine
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified April 2010
  • Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

    Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified September 2010
  • Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy

    Conditions:   Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Nonneoplastic Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: sunitinib malate;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
    Sponsors:   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
    Recruiting - verified September 2010
  • Collecting and Storing Tissue From Young Patients With Cancer

    Condition:   Cancer
    Interventions:   Genetic: DNA analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2010
  • Efficacy and Safety of Panobinostat (LBH5789) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

    Conditions:   Refractory Leukemia;   Acute Myelogenous Leukemia
    Intervention:   Drug: Panobinostat/LBH589
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified September 2010
  • Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

    Conditions:   Anemia;   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Biological: epoetin alfa;   Drug: lenalidomide
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2010
  • Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes

    Conditions:   Fatigue;   Myelodysplastic Syndromes
    Interventions:   Other: questionnaire administration;   Procedure: fatigue assessment and management;   Procedure: observation;   Procedure: quality-of-life assessment
    Sponsor:   Gruppo Italiano Malattie EMatologiche dell'Adulto
    Recruiting - verified February 2010
  • Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Stem Cell Transplant Cope With Late Complications

    Conditions:   Cancer Survivor;   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   Atypical Chronic Myeloid Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   De Novo Myelodysplastic Syndromes;   Depression;   Disseminated Neuroblastoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Fatigue;   Long-term Effects Secondary to Cancer Therapy in Adults;   Myelodysplastic/Myeloproliferative Disease, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Psychosocial Effects of Cancer and Its Treatment;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma
    Interventions:   Other: internet-based intervention;   Other: questionnaire administration;   Procedure: psychosocial assessment and care;   Procedure: assessment of therapy complications;   Procedure: management of therapy complications;   Procedure: fatigue assessment and management;   Other: counseling intervention
    Sponsor:   Fred Hutchinson Cancer Research Center
    Recruiting - verified August 2010
  • Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
    Interventions:   Drug: cyclosporine ophthalmic emulsion;   Other: placebo
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified September 2010
  • Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

    Conditions:   Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous Condition;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2010
  • American Ginseng in Treating Patients With Fatigue Caused by Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Fatigue;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Dietary Supplement: American ginseng;   Other: placebo
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2010
  • T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

    Conditions:   Acute Myelogenous Leukemia;   Lymphoid Leukemia;   Chronic Myelogenous Leukemia;   Malignant Lymphoma;   Hodgkin's Disease;   Chronic Lymphocytic Leukemia;   Myeloproliferative Disorder;   Anemia, Aplastic;   Myelodysplastic Syndromes
    Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Drug: Stem cells;   Drug: Campath
    Sponsor:   University of Chicago
    Recruiting - verified August 2010
  • A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced of Refractory Leukemia or Myelodysplastic Syndrome.

    Conditions:   Leukemia, Myeloid, Acute;   Precursor Cell Lymphoblastic Leukemia-Lymphoma;   Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Myelodysplastic Syndromes;   Leukemia, Lymphocytic, Chronic, B-Cell
    Intervention:   Drug: JNJ-26481585.
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified August 2010
  • Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

    Conditions:   MDS;   Myelodysplastic Syndromes;   Thrombocytopenia
    Interventions:   Drug: Placebo;   Biological: Romiplostim
    Sponsor:   Amgen
    Recruiting - verified August 2010
  • Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy

    Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Acute Undifferentiated Leukemia;   Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Interventions:   Procedure: MRI and cognitive evaluation;   Procedure: MRI and cognitive evaluation;   Procedure: brain MRI study and a brief neuropsychological evaluation
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Weill Medical College of Cornell University;   Citigroup Biomedical Imaging Center at Weill Cornell Medical Center
    Recruiting - verified September 2010
  • A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy

    Conditions:   Cancer;   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Fludarabine, Cyclophosphamide;   Procedure: Transplantation
    Sponsor:   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified August 2010
  • Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

    Condition:   Leukemia
    Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic bone marrow transplantation
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2010
  • Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

    Conditions:   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts
    Interventions:   Drug: busulfan;   Drug: etoposide;   Radiation: intensity-modulated radiation therapy;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: tomotherapy
    Sponsor:   City of Hope Medical Center
    Recruiting - verified August 2010
  • Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

    Condition:   Cancer
    Interventions:   Drug: fentanyl sublingual spray;   Other: questionnaire administration
    Sponsor:   Insys Therapeutics Inc
    Recruiting - verified October 2008
  • Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)

    Conditions:   Leukemia;   Myelodysplastic Syndrome
    Intervention:   Behavioral: Interview
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified September 2010
  • Identification of Key Blood Molecular Markers for Immunotherapy

    Conditions:   Carcinomas (Including Squamous Cell and Adenocarcinoma);   Anal Cancer;   Bile Duct Cancer (Cholangiocarcinoma);   Bladder (Urothelial, Transitional Cell) Cancer;   Blood and Marrow Transplant (BMT);   Bone Cancer;   Brain (Nervous System) Cancers;   Breast Cancer;   Colon/Rectal Cancer;   Endocrine Cancer;   Esophageal Cancer;   Eye Cancer;   Gall Bladder Cancer;   Gastric (Stomach) Cancer;   Gastro-Esophageal(GE) Junction Cancer;   Gastrointestinal Stromal Tumor (GIST);   Gynecologic Cancers;   Head and Neck Cancers;   Hepatobiliary Cancers;   Kidney (Renal Cell) Cancer;   Leukemia;   Lung Cancer;   Lymphoma: Hodgkin;   Lymphomas: Non-Hodgkin;   Mesothelioma;   Multiple Myeloma;   Myelodysplastic Syndromes (MDS);   Myeloproliferative Disorders (MPD);   Neuroendocrine Tumors;   Pancreatic Cancer;   Prostate Cancer;   Skin Cancer;   Soft Tissue Sarcoma;   Testicular Cancer;   Thymus Cancer;   Thyroid Cancer
    Intervention:   Procedure: phlebotomy
    Sponsor:   Stanford University
    Recruiting - verified August 2010
  • Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)

    Conditions:   Hematology;   MDS;   Myelodysplastic Syndromes;   Thrombocytopenia
    Intervention:   Drug: Romiplostim (formerly AMG 531)
    Sponsor:   Amgen
    Recruiting - verified September 2010
  • Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants

    Conditions:   Chronic Myelogenous Leukemia;   Acute Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome
    Intervention:   Device: Miltenyi CliniMACS CD34 Reagent System
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified July 2010
  • Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

    Conditions:   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: thioguanine
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2010
  • Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

    Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
    Intervention:   Drug: Revlimid
    Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
    Recruiting - verified August 2010
  • Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

    Conditions:   Carcinomas (Including Squamous Cell and Adenocarcinoma);   Anal Cancer;   Bile Duct Cancer (Cholangiocarcinoma);   Bladder (Urothelial, Transitional Cell) Cancer;   Blood and Marrow Transplant (BMT);   Bone Cancer;   Brain (Nervous System) Cancers;   Breast Cancer;   Colon/Rectal Cancer;   Endocrine Cancer;   Esophageal Cancer;   Eye Cancer;   Gall Bladder Cancer;   Gastric (Stomach) Cancer;   Gastro-Esophageal(GE) Junction Cancer;   Gastrointestinal Stromal Tumor (GIST);   Gynecologic Cancers;   Head and Neck Cancers;   Hepatobiliary Cancers;   Kidney (Renal Cell) Cancer;   Leukemia;   Lung Cancer;   Lymphoma: Hodgkin;   Lymphomas: Non-Hodgkin;   Mesothelioma;   Multiple Myeloma;   Myeloproliferative Disorders (MPD);   Myelodysplastic Syndromes (MDS);   Neuroendocrine Tumors;   Pancreatic Cancer;   Prostate Cancer;   Skin Cancer;   Soft Tissue Sarcoma;   Testicular Cancer;   Thymus Cancer;   Thyroid Cancer
    Intervention:   Procedure: blood draw
    Sponsor:   Stanford University
    Recruiting - verified August 2010
  • Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

    Conditions:   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: azacitidine;   Drug: entinostat
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2010
  • Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

    Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Neuroblastoma;   Pulmonary Complications;   Sarcoma
    Interventions:   Biological: etanercept;   Drug: methylprednisolone
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2010
  • Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant

    Condition:   Cancer
    Interventions:   Procedure: music therapy;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   National Institute of Nursing Research (NINR)
    Recruiting - verified September 2010
  • Oral Clofarabine Study in Patients With Myelodysplastic Syndrome

    Conditions:   Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia
    Intervention:   Drug: Clofarabine
    Sponsors:   M.D. Anderson Cancer Center;   Genzyme
    Recruiting - verified August 2010
  • Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia

    Conditions:   Leukemia;   Myelodysplastic Syndromes
    Intervention:   Drug: BAY 43-9006
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified September 2010
  • Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

    Condition:   Cancer
    Interventions:   Biological: therapeutic allogeneic lymphocytes;   Other: laboratory biomarker analysis
    Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
    Recruiting - verified May 2009
  • Fludarabine and Total-Body Irradiation Followed By a Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified August 2010
  • Study of Late-Occurring Complications in Childhood Cancer Survivors

    Condition:   Cancer
    Interventions:   Genetic: cytogenetic analysis;   Genetic: mutation analysis;   Genetic: polymorphism analysis;   Other: questionnaire administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2010
  • Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma

    Conditions:   Leukemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
    Interventions:   Genetic: chromosomal translocation analysis;   Genetic: cytogenetic analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified September 2010

Main Menu
Clinical Trial Locations
Clinical Trial Categories
Sponsors/Recruiting